[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ischemic-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ischemic-stroke":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,252,0,25,[9,52,81,109,138,163,188,216,234,260,281,306,332,350,377,406,438,461,498,524,553,583,605,631,651],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100630767","continuous-dual-aspiration-technique-with-zoom-system-for-stroke-100630767",false,"NCT07491952","Continuous Dual Aspiration Technique With Zoom System for Stroke","Clinical Evaluation of Continuous Dual Aspiration Technique With Zoom System for Stroke (ADAPT 2.0)","ADAPT 2 0","Inclusion Criteria:\n\n1. Subject is ≥ 18 years of age\n2. Subject or legally authorized representative has provided written informed consent prior to any study-specific procedures and no later than 72 hours after the index procedure\n3. Pre-stroke mRS 0-2\n4. Subject is undergoing or has undergone an aspiration thrombectomy using the Zoom System with Continuous Dual Aspiration Technique (CDAT) as the first line device within its intended use\n\nExclusion Criteria:\n\n1. Subjects with a life expectancy of less than 6 months\n2. Female subject who is known to be pregnant at time of admission\n3. Any intracranial hemorrhage in the qualifying head CT or MRI\n4. Presence of tandem internal carotid artery occlusion, multiple occlusion locations (e.g., cavernous ICA and M1, separate M2 occlusions, etc.), or occlusions in multiple territories (e.g., MCA and ACA, bilateral, etc.).\n5. In the opinion of the Investigator, the patient is not a suitable candidate for intervention with the Zoom System\n6. Subject is currently enrolled in or planned to be enrolled in any concurrent interventional study that may impact the safety or performance data collected in this study","ALL","18 Years",{"count":21,"type":22},750,"ESTIMATED","OBSERVATIONAL","This study is designed to evaluate the effectiveness, safety and clinical performance of ADAPT 2.0, first-line aspiration neurothrombectomy with Zoom System with Continuous Dual Aspiration Technique (CDAT).",[26,27],"Ischemic Stroke","Acute Stroke",[29,30,31,32,33,34,35,36,37,38],"stroke","thrombectomy","Zoom","aspiration","reperfusion","mRS","ADAPT","continuous","dual aspiration","Zoom System","RECRUITING","2026-06-26",{"date":42,"type":43},"2026-06-29","ACTUAL",{"date":45,"type":43},"2026-03-24",{"date":47,"type":22},"2030-06-01",{"name":49,"class":50},"Imperative Care, Inc.","INDUSTRY",16,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":68,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100642146","phase-2-a-study-of-probiotics-in-patients-with-acute-ischemic-stroke-100642146","NCT07651332","A Study of Probiotics in Patients With Acute Ischemic Stroke","Placebo-Controlled, Double-Blind, Phase 2 Trial of Probiotic Supplementation in Acute Ischemic Stroke","PRO-STROKE","Inclusion Criteria:\n\n1. Age ≥ 60 years;\n2. Diagnosis of ischemic stroke; (1)Ischemic stroke is defined as clinically manifest acute neurological deficits linked to an acute cerebral infarct in the anterior circulation; (2)Central retinal artery occlusion or likely central retinal artery occlusion are not considered ischemic strokes in the context of this trial;\n3. Randomization within 72 hours of symptom onset;\n4. Ability to provide written informed consent;\n5. Baseline NIHSS \\>=4;\n6. Pre-stroke mRS \\\u003C=2;\n\nExclusion Criteria:\n\n1. Suspected lack of compliance;\n2. Presence of moderate to severe dysphagia;\n3. Current participation in other interventional trials or recent participation (within the last 30 days) in an interventional trial;\n4. Known allergy or hypersensitivity to trial compounds components or placebo;\n5. No known history before randomization of imminently life-shortening medical conditions or any other reason, including any physical, psychological, or psychiatric condition that in the investigator's opinion would compromise the safety or interfere with the subject's participation in this study, or would make the subject an unsuitable candidate to receive study drug, or would put the subject at risk by participating in the study;\n6. Malignant diseases including active malignancies with a life expectancy of less than 3 months;\n7. Major gastro-intestinal (GI) surgery, chronic inflammatory diseases of the gut and significant GI-neoplasms;","60 Years",{"count":62,"type":22},220,"INTERVENTIONAL",[65],"PHASE2","The primary objective of this study is to evaluate the effect of daily oral administration of the probiotic supplement OMNi-BiOTiC® SR-9 for 90 days, compared to placebo, on gut microbiome beta diversity in patients aged 60 years or older with acute ischemic stroke.",[26],[69],"ischemic stroke","NOT_YET_RECRUITING","2026-06-16",{"date":73,"type":43},"2026-06-17",{"date":75,"type":22},"2026-09-01",{"date":77,"type":22},"2027-12-31",{"name":79,"class":80},"Capital Medical University","OTHER",{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":63,"phases":91,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100641099","feasibility-of-a-remotely-delivered-step-count-intervention-in-chronic-stroke-100641099","NCT07649135","Feasibility of a Remotely Delivered Step Count Intervention in Chronic Stroke","Feasibility of Engaging Stroke Survivors in a Brief Step Count Intervention During Chronic Stroke","PA-ChatS","Inclusion Criteria:\n\n* Stroke diagnosis confirmed by imaging\n* Stroke occurred 6 or more months before study enrollment\n* Meet criteria for \"inactive\" on the International Physical Activity Questionnaire-Short Form\n* Able to identify a support person that they interact with in-person at least once per week\n* Able and willing to participate fully in the study and provide informed consent or proxy consent with participant assent\n\nExclusion Criteria:\n\n* Currently receiving care in a transitional care unit, skilled nursing facility, or other institutional care setting\n* Currently receiving outpatient neurorehabilitation services (e.g., physical therapy, occupational therapy, speech therapy)\n* Severe cognitive or communication impairments (inability to respond accurately to complete study screening questions or to provide informed consent or assent)\n* Currently pregnant or expecting to become pregnant in the next 8 weeks Comorbid neurological disorder (Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, myasthenia gravis, dementia, Alzheimer's disease, Huntington's disease, glioblastoma, spinal cord injury, cerebral palsy)\n* Comorbid cancer, currently undergoing chemotherapy or radiation treatment\n* Received inpatient treatment or was hospitalized for a psychiatric condition and\u002For alcohol or substance abuse within the past 12 months\n* Current diagnosis of a terminal illness and\u002For currently receiving hospice care\n* History of allergic reaction to adhesives that precludes the use of an adhesive necessary for adherence to activPAL measurement\n* Uses wheelchair as primary mobility aid outside of home setting\n* Inability to speak, read, or understand English\n* Concurrent participation in another rehabilitation intervention research study\n* Resides more than 50 miles outside of the Twin Cities, Minnesota metropolitan area\n* Investigator discretion for safety or adherence reasons",{"count":90,"type":22},24,[92],"NA","The goal of this study is to explore the feasibility of a new approach to rehabilitation that focuses on step count. Participants will complete 6 telephone or Zoom-based sessions with an occupational therapist over 6 weeks and use a step count tracker during that time. They will also complete questionnaires, assessments, surveys, and physical activity measurements during study weeks 0 (baseline), 3 (mid-point), 7 (post-intervention) and 12 (follow-up).",[95,26,96],"Stroke","Hemorrhagic Stroke",[98,99,100],"physical activity","behavior change","rehabilitation",{"date":102,"type":43},"2026-06-18",{"date":104,"type":22},"2026-06-22",{"date":106,"type":22},"2027-01",{"name":108,"class":80},"University of Minnesota",{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100641203","virtual-stroke-units-versus-conventional-stroke-unit-care-in-non-thrombectomy-candidate-patients-100641203","NCT07635498","Virtual Stroke Units Versus Conventional Stroke Unit Care in Non-Thrombectomy-Candidate Patients.","Virtual Stroke Units Versus Conventional Stroke Unit Care in Non-Thrombectomy-Candidate Patients: A Non-Inferiority Prospective Cohort Study","VSU","Inclusion Criteria\n\n* Age ≥ 18 years.\n* Diagnosis of acute stroke (ischemic or hemorrhagic) confirmed by clinical assessment and neuroimaging (CT and\u002For MRI) within 24 hours of symptom onset or last-seen-well.\n* Not a candidate for mechanical thrombectomy according to current clinical guidelines.\n* Admission to a participating hospital (Hospital de Riotinto, Hospital San Juan de Dios del Aljarafe, or Hospital Universitario Virgen Macarena).\n* Signed informed consent by the participant or legal representative. Exclusion Criteria\n* Pre-stroke modified Rankin Scale (mRS) ≥ 4.\n* Life expectancy \\\u003C 6 months due to non-stroke comorbid conditions.\n* Inability to complete protocolized follow-up (geographical, social, or clinical reasons).\n* Concurrent participation in another interventional clinical trial that may affect study endpoints.\n* Refusal to provide informed consent.",{"count":118,"type":22},726,"Stroke is the leading cause of acquired disability in adults and a major cause of mortality worldwide; in Spain, Andalusia shows the highest stroke-related mortality rate. Comprehensive Stroke Units (SU) are the gold-standard organizational model for acute stroke care; however, only a fraction of patients have direct access to an SU, particularly those not eligible for mechanical thrombectomy who are admitted to regional or district hospitals without on-site SU capacity.\n\nThe Virtual Stroke Unit (VSU) concept extends specialized stroke care to non-SU hospitals by combining standardized in-hospital monitoring boxes with synchronous remote multidisciplinary assessment by a stroke neurologist and stroke nurse from a reference center, via the regional telemedicine platform (CATI).\n\nThis prospective, multicenter, non-inferiority cohort study compares effectiveness, safety, and feasibility of VSU care versus conventional SU care in patients with acute ischemic or hemorrhagic stroke who are not candidates for mechanical thrombectomy. Recruitment targets 363 patients per arm (726 total). The primary outcome is death or dependency at 3 months (modified Rankin Scale 3-6) - the canonical measure of stroke-unit effectiveness - with functional independence (mRS 0-2), adherence to the stroke-unit care quality bundle, safety, mortality, recurrence, length of stay, satisfaction (TUQ\u002FTSQ\u002FTMPQ) and cost-effectiveness as secondary outcomes.",[95,121,26],"Stroke Hemorrhagic",[123,124,125,126,127,128,129],"Virtual Stroke Unit","Telemedicine","Telestroke","Stroke Unit","Healthcare delivery system","Non-inferiority","Modified Rankin Scale",{"date":102,"type":43},{"date":132,"type":43},"2026-04-01",{"date":134,"type":22},"2028-03-31",{"name":136,"class":80},"Hospital Universitario Virgen Macarena",1,{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":63,"phases":148,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":162},"100514299","early-closure-of-left-atrial-appendage-for-patients-with-atrial-fibrillation-and-ischemic-stroke-despite-anticoagulation-therapy-100514299","NCT05976685","Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy","Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic StrokE Despite Anticoagulation Therapy","ELAPSE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Written informed consent\n* Permanent, persistent, or paroxysmal spontaneous AF previously known or diagnosed during the index hospitalization.\n* Recent (≤3 months) symptomatic ischemic stroke.\n* Active and ongoing anticoagulation therapy at stroke onset assessed based on medical history (i.e. any therapeutic oral anticoagulation therapy \\[Vitamin K antagonist\u002FDOAC according to prescription recommendations for AF; inadequate low-dose DOAC therapy allowed for inclusion\\] not stopped\u002Fpaused for \\>48 hours due to any reason, i.e. medical intervention or non-adherence).\n* Active or planned long-term therapy with DOAC\n\nExclusion Criteria:\n\n* Contraindications to DOAC therapy\n* Life expectancy \\\u003C1 year according to the opinion of the investigator\n* Stroke due to: Ipsilateral intra\u002Fextracranial high-grade stenosis, Isolated lacunar stroke, Other well-defined stroke aetiologies (i.e., endocarditis, vasculitis, Reversible Cerebral Vasoconstriction Syndrome \\[RCVS\\], Posterior Reversible Encephalopathy Syndrome \\[PRES\\], cerebral sinus venous thrombosis)\n* Previous persistent foramen ovale or atrial septum defect closure.\n* Rheumatic heart disease\n* Severe heart valve disease that requires treatment (severe aortic stenosis or regurgitation, severe mitral stenosis or regurgitation).\n* Contraindications for TEE (relevant esophageal varices, esophageal stricture, history of esophageal cancer).\n* Cardiac or non-cardiac surgical procedure within 30 days of randomization\n* Enrolled in another investigation of a cardiovascular device or investigating secondary prevention therapy.\n* Severely reduced Left Ventricular Ejection Fraction (LVEF) \\\u003C30%.\n* Severe renal impairment as described in the summary of medicinal product characteristics for the chosen DOAC (e.g. rivaroxaban, apixaban and edoxaban creatinine clearance \\\u003C15 ml\u002Fmin; dabigatran creatinine clearance \\\u003C30 ml\u002Fmin).\n* Hypertrophic cardiomyopathy\n* Intracardiac tumor\n* Ventricular thrombus\n* Acute cardiac decompensation\n* LAA is obliterated or surgically ligated\n* Persistent proximal LAA thrombus despite 4 weeks of anticoagulation (if a proximal thrombus in the LAA is found, anticoagulation with vitamin K antagonist (INR 2.5-3.5) may be started, and if the thrombus disappears, the patient may be eligible for LAAO)\n* Pregnancy or breastfeeding (pregnancy test in urine or blood to be performed at screening for women of childbearing potential)",{"count":147,"type":22},482,[92],"Atrial fibrillation (AF) is one of the most common cardiac arrhythmias and cardioembolic stroke due to AF is its major complication. Direct oral anticoagulants (DOAC) reduce the risk of cardioembolism in patients with AF. Despite DOAC therapy, there is a significant residual stroke risk of 1-2%\u002Fyear. Recent data from the Swiss Stroke Registry found 38% of patients with AF and ischemic stroke were on prior anticoagulant therapy (approximately 400 patients per year in Switzerland). The investigators found in a prior observational study, that patients with AF who have ischemic stroke despite anticoagulation are at increased risk of having another ischemic stroke (HR 1.6; 95% confidence interval, CI 1.1-2.1). Combining observational data from 11 international stroke centres, the investigators found that the majority of ischemic strokes despite anticoagulation in patients with AF is \"breakthrough\" cardioembolism (76% of patients) and only a minority of 24% is related to other causes unrelated to AF. Optimal secondary prevention strategy is unknown. The investigators have conducted two independent observational studies including together \\>4000 patients but did not identify any strategy (e.g. switch to different DOAC, additional antiplatelet therapy) that seems superior. A recent randomized controlled trial on surgical occlusion of the left atrial appendage (LAAO) found that LAAO may provide additional protection from ischaemic stroke in addition to oral anticoagulation. Triggered by this finding, the investigators performed a matched retrospective observational study and found that patients with AF and stroke despite anticoagulation who received a combined mechanical-pharmacological therapy (DOAC therapy + LAAO) had lower rates of adverse outcomes compared to those with DOAC therapy alone. Therefore, the investigators hypothesize that in patients with AF and ischemic stroke despite anticoagulant therapy, LAAO in addition to anticoagulation with a DOAC is superior to DOAC therapy alone. The investigators propose an international, multi-center randomized controlled two-arm trial to assess the effect of LAAO in patients with AF suffering from strokes despite anticoagulation therapy and without competing stroke etiology. The investigators will use the PROBE design with blinded endpoint assessment. The investigators will enrol patients with non-valvular AF and a recent ischemic stroke despite anticoagulation therapy at stroke onset. Patients will be randomized 1:1 to receive LAAO + DOAC therapy (experimental arm) or DOAC therapy alone (standard treatment arm). The primary endpoint is the first occurrence of a composite outcome of recurrent ischemic stroke, systemic embolism and cardiovascular death during follow-up. Secondary outcomes include individual components of the primary composite outcome, safety outcomes (i.e. symptomatic intracranial haemorrhage, major extracranial bleeding, serious device- or procedure-related complication), functional outcome (modified Rankin Scale) and patient-oriented outcomes. The minimum follow-up is 6 months and all patients will receive follow-ups every 6 months until end of study, the maximal follow-up will be 48 months. Based on prior observational data from the investigators' group and others (5 observational studies, \\>5000 patients), the investigators estimate the proportion of patients with the primary outcome in the standard treatment arm to be 18% in the first year and 9% in the second year (=cumulative 27% after 2 years). A relative risk reduction of 40% at 2 years would be clinically relevant. Based on these assumptions and a log-rank test, the investigators would need 98 events for a power of 80% at an alpha-level of 5%. Assuming a recruitment rate of 52, 118, 156 and 156 patients in years 1 to 4, an additional 6 months of follow-up (mean follow-up time of 2.1 years) and a uniform drop-out rate of 7.5% per year, 482 patients would need to be enrolled. How to treat patients with an ischemic stroke despite anticoagulation is a major yet unresolved clinical dilemma. This trial has the potential to answer the question whether LAAO plus DOAC therapy is superior to current standard of care for patients with AF who have ischemic stroke despite anticoagulation.",[26,151],"Atrial Fibrillation",[95,153,154],"Direct oral anticoagulation","Left atrial appendage occlusion",{"date":73,"type":43},{"date":157,"type":43},"2024-05-01",{"date":159,"type":22},"2028-06-01",{"name":161,"class":80},"Insel Gruppe AG, University Hospital Bern",29,{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":172,"conditions":173,"keywords":175,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":137},"100641638","cerebrospinal-fluid-mitochondrial-biomarkers-in-ischemic-stroke-and-alzheimer-disease-100641638","NCT07600996","Cerebrospinal Fluid Mitochondrial Biomarkers in Ischemic Stroke and Alzheimer Disease","A Prospective Observational Study of Cerebrospinal Fluid Mitochondrial Biomarkers Measured by Flow Cytometry in Patients With Ischemic Stroke and Alzheimer Disease Controls","Inclusion Criteria:\n\n* Age 18 years or older. Patients treated at Xuanwu Hospital, Capital Medical University between March 2026 and May 2026.\n\nDiagnosis of ischemic stroke or Alzheimer disease according to standard clinical diagnostic criteria.\n\nDiagnostic lumbar puncture performed for clinical indications as part of routine medical care.\n\nAvailability of residual cerebrospinal fluid after completion of clinically required testing.\n\nAbility to provide written informed consent, or availability of a legally authorized representative to provide consent when appropriate.\n\nFor ischemic stroke patients, availability of baseline neurological assessment and planned follow-up for 90-day modified Rankin Scale assessment.\n\nExclusion Criteria:\n\n* Lumbar puncture performed solely for research purposes rather than clinical indication.\n\nInsufficient residual cerebrospinal fluid volume for research flow cytometry analysis.\n\nGrossly bloody or severely contaminated cerebrospinal fluid sample that precludes reliable flow cytometry analysis.\n\nKnown central nervous system infection, malignant meningitis, or other inflammatory or neoplastic condition that, in the investigator's judgment, may substantially confound cerebrospinal fluid mitochondrial measurements.\n\nInability to obtain informed consent from the participant or legally authorized representative.\n\nMissing key clinical outcome data, including admission NIHSS, discharge NIHSS, or planned 90-day mRS follow-up for ischemic stroke participants.\n\nAny condition judged by the investigator to make the participant unsuitable for inclusion in the study.",{"count":171,"type":22},40,"This prospective observational study aims to investigate cerebrospinal fluid mitochondrial biomarkers in patients with ischemic stroke and Alzheimer disease controls who undergo diagnostic lumbar puncture for clinical indications at Xuanwu Hospital, Capital Medical University.\n\nResidual cerebrospinal fluid samples will be analyzed by flow cytometry to quantify mitochondrial content, mitochondrial membrane potential, and cellular or vesicular source-related markers. The flow cytometry panel will include MitoTracker, JC-1, and membrane-associated markers including CD45, CD41, CD24, vWF, and EAAT1.\n\nIn patients with ischemic stroke, the study will further examine whether cerebrospinal fluid mitochondrial measurements are associated with neurological severity and functional outcomes, including admission and discharge NIHSS scores and the 90-day modified Rankin Scale score. Alzheimer disease patients undergoing diagnostic lumbar puncture will serve as disease controls for biomarker comparison.",[26,174],"Alzheimer Disease (AD)",[176,177,178,179,180],"Cerebrospinal fluid","Mitochondria","MitoTracker","NIHSS","Stroke outcome","2026-06-14",{"date":71,"type":43},{"date":184,"type":43},"2026-03-01",{"date":186,"type":22},"2026-08-30",{"name":79,"class":80},{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":63,"phases":199,"briefSummary":200,"conditions":201,"keywords":202,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":212,"leadSponsor":214,"locationsCount":137},"100642716","phase-2-a-phase-2b-trial-of-lesion-network-mapping-guided-ctbs-for-motor-recovery-after-acute-ischemic-stroke-100642716","NCT07645560","A Phase 2b Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After Acute Ischemic Stroke","Lesion Network Mapping-Navigated Continuous Theta-Burst Stimulation for Motor Recovery in Acute Ischemic Stroke: A Randomized, Double-Blind, Sham-Controlled, Multicentre Phase 2b Trial: MASTRE-2","MASTRE-2","Inclusion Criteria:\n\n1. Age 18-80 years.\n2. Ischemic stroke onset within the past 14 days.\n3. Unilateral, supratentorial ischemic stroke confirmed by CT or MRI.\n4. Pre-stroke modified Rankin Scale (mRS) score of 0-1.\n5. NIH Stroke Scale (NIHSS) total score 6-25, with item 1a ≤ 1 point, and at least one of items 5a, 5b, 6a, or 6b ≥ 2 points.\n6. Written informed consent signed by the patient or the patient's legally authorized representative.\n\nExclusion Criteria:\n\n1. Contraindications to TMS (e.g. cranial metallic foreign bodies, cardiac pacemaker, implanted drug pump, cochlear implant).\n2. History of epilepsy or seizure, intracranial hypertension, tumor, or other serious neurological disease.\n3. Midline shift or parenchymal mass effect on cranial CT or other imaging.\n4. CT or MRI evidence of bilateral acute cerebral infarction or infratentorial acute infarction (brainstem or cerebellum).\n5. Evidence of acute intracranial hemorrhage, including spontaneous intracerebral hemorrhage, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage.\n6. Pre-stroke mRS ≥ 2.\n7. Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg despite antihypertensive treatment.\n8. Pregnant or breastfeeding women, or women planning pregnancy within 90 days.\n9. Severe psychiatric disorders or dementia (or other conditions) precluding informed consent or follow-up.\n10. Concomitant malignant tumor or severe systemic disease with life expectancy \\\u003C 90 days.\n11. Participation in any other interventional clinical study within 30 days before randomization, or currently enrolled in such a study.","80 Years",{"count":198,"type":22},60,[65],"This Phase 2b study will evaluate whether lesion network mapping-guided continuous theta burst stimulation (cTBS) can improve recovery after acute ischemic stroke. The treatment uses each participant's brain imaging to identify individualized stimulation targets related to stroke symptoms. Participants will receive either active cTBS or a sham procedure in addition to standard stroke care. The study will assess the efficacy and safety of this personalized brain stimulation approach and support planning for future confirmatory trials.",[26],[203,204,205,206,207],"ishchemic stroke","Lesion network mapping","Continuous theta-burst stimulation","Motor function","Neuronavigation","2026-06-12",{"date":210,"type":43},"2026-06-15",{"date":210,"type":22},{"date":213,"type":22},"2027-12-30",{"name":215,"class":80},"Beijing Tiantan Hospital",{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":196,"enrollmentInfo":223,"targetDuration":4,"studyType":63,"phases":225,"briefSummary":227,"conditions":228,"keywords":229,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":230,"startDateStruct":231,"completionDateStruct":232,"leadSponsor":233,"locationsCount":137},"100642075","phase-3-a-phase-3-trial-of-lesion-network-mapping-guided-ctbs-for-motor-recovery-after-acute-ischemic-stroke-100642075","NCT07645586","A Phase 3 Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After Acute Ischemic Stroke","Lesion Network Mapping-Navigated Continuous Theta-Burst Stimulation for Motor Recovery in Acute Ischemic Stroke: A Randomized, Double-Blind, Sham-Controlled, Multicentre Phase 3 Trial: MASTRE-3","MASTRE-3",{"count":224,"type":22},584,[226],"PHASE3","This Phase 3 study will evaluate whether lesion network mapping-guided continuous theta burst stimulation (cTBS) can improve recovery after acute ischemic stroke. The treatment uses each participant's brain imaging to identify individualized stimulation targets related to stroke symptoms. Participants will receive either active cTBS or a sham procedure in addition to standard stroke care. The study will assess whether this personalized brain stimulation approach improves functional recovery and is safe for patients after ischemic stroke.",[26],[203,204,205,206,207],{"date":210,"type":43},{"date":210,"type":22},{"date":213,"type":22},{"name":215,"class":80},{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":63,"phases":244,"briefSummary":245,"conditions":246,"keywords":247,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":137},"100437390","goal-attainment-scaling-in-upper-limb-spasticity-treatment-100437390","NCT04975646","Goal Attainment Scaling in Upper Limb Spasticity Treatment","Goal Attainment Scaling in Upper Limb Spasticity Treatment With Botulinum Toxin and the Influence of Regular Exercise for Spastic Upper Limb on Quality of Life in Patients After Stroke","GASBTX","Inclusion Criteria:\n\n* patient's or caregiver's approval\n* ischemic or hemorrhagic stroke diagnosed using head CT\u002FMRI\n* at least one upper limb muscle spasticity (MAS ≥ 3)\n* candidate for BTX-A treatment or already given BTX-A in the past\n* patient's or caregiver's capability for goal attainment protocol cooperation (Mini Mental Examination ≥ 24 points)\n\nExclusion Criteria:\n\n* aphasic patients without caregiver's presence\n* other neurological or musculoskeletal diseases that could affect the treatment outcome",{"count":243,"type":22},70,[92],"Patients after stroke with upper limb spasticity treated with botulinum toxin-A (BTX-A) will be included in this two-part study. In the first part, goal attainment scaling and comprehensive assessment of motor functioning will be performed before BTX-A application and after two weeks. In the second part, the patients will be randomised into a test group performing prescribed regular exercise for two weeks and a control group exercising at their own discretion during the same period, whereby the patients' health-related quality of life will be assessed at the beginning and end of the two-week period.",[26,96],[100,248,249,250,251],"spasticity","botulinum toxin A","goal setting","spasticity-related quality of life","2026-06-11",{"date":210,"type":43},{"date":255,"type":43},"2021-01-03",{"date":257,"type":22},"2026-10",{"name":259,"class":80},"University Rehabilitation Institute, Republic of Slovenia",{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":18,"minAge":267,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":63,"phases":270,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":276,"completionDateStruct":277,"leadSponsor":279,"locationsCount":137},"100605010","proprioceptive-error-correction-for-post-stroke-upper-limb-rehabilitation-100605010","NCT07156955","Proprioceptive Error Correction for Post-Stroke Upper Limb Rehabilitation","Proprioceptive Error Correction Technique Development to Promote Post-stroke Upper Limbs Motor Rehabilitation","Inclusion Criteria:\n\n* Diagnosed with ischemic or hemorrhagic stroke\n* Stroke confirmed by CT or MRI\n* Stroke patients with proprioceptive sensory deficits\n* Chronic stroke patients with onset at least 3 months prior\n* Able to voluntarily flex and extend the elbow joint\n* Age 19 years or older\n* Provide written informed consent (participant or legal representative)\n\nExclusion Criteria:\n\n* Severe pain during elbow joint movement\n* Elbow joint contracture, spasticity, ataxia, musculoskeletal disorders, fractures, - non-healing ulcers, or open wounds\n* Progressive or unstable stroke\n* Presence of unilateral neglect\n* Coexisting severe neurological disorders\n* Major psychiatric disorders such as major depressive disorder, schizophrenia, bipolar disorder, or dementia Presence of a pacemaker","19 Years",{"count":269,"type":22},3,[92],"The investigators aim to develop sensory transformation and augmentation technologies that minimize the impact of proprioceptive errors, thereby significantly enhancing motor learning and rehabilitation of the upper limbs. This study is designed to test proprioceptive error compensation techniques in stroke patients.\n\nThe human nervous system often receives mismatched information from vision and proprioception during upper limb control, resulting in conflicting sensory inputs that limit the effectiveness of motor learning. In other words, real-time sensory feedback - a critical component of motor learning in the nervous system - is not reliably delivered. Therefore, this study seeks to resolve sensory conflicts by providing additional sensory information through electrical stimulation, with the goal of dramatically improving the effectiveness of motor learning.",[26,273],"Proprioception","2026-06-10",{"date":208,"type":43},{"date":75,"type":22},{"date":278,"type":22},"2027-03-30",{"name":280,"class":80},"Sungkyunkwan University",{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":289,"sex":18,"minAge":290,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":293,"conditions":294,"keywords":297,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":137},"100479078","platelet-expression-of-fcriia-and-arterial-hemodynamics-to-predict-recurrent-stroke-in-intracranial-atherosclerosis-100479078","NCT05518305","Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis","Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosi","FCG","Inclusion Criteria:\n\n* Stroke is defined as symptoms lasting \\>24 hours and associated with imaging evidence of acute ischemia in the distribution of the stenotic vessel on head CT or brain MRI. Minor stroke is defined as NIHSS\\\u003C6, as used in prior studies.\n* Eligible TIA, defined as transient neurological symptoms lasting \\\u003C24 hours, need to be: a) accompanied by DWI abnormalities in the distribution of the stenotic artery; or b) multiple (\\>1), stereotyped events associated with unequivocal ischemic symptoms (i.e. weakness, aphasia, diplopia), and attributed to the symptomatic artery. The intent of these restrictive inclusion criteria for TIA is to exclude potential stroke mimics.\n* ICAD should involve the intracranial carotid, middle cerebral, intracranial vertebral or basilar arteries. Isolated anterior and posterior cerebral artery stenosis is not included as it is uncommon in these locations and non-invasive criteria for high-grade ICAD are not well established for these vessels.\n* Stenosis 50-99% will be quantified by CTA. The criteria for 50-99% are: measured stenosis by WASID criteria (percent stenosis = (1-\\[diameter stenosis\u002Fdiameter normal\\]) x 100%.\n* Age ³30; those 30-49 years of age must also have the presence of established atherosclerotic disease in another vascular bed (coronary, extracranial carotid, peripheral) or the presence of 2 or more risk factors (hypertension, diabetes mellitus, hyperlipidemia, tobacco abuse within the last 2 years). The rationale for this criterion is to exclude non-atherosclerotic vasculopathies.\n* Provide informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Other determined etiology or established cause of the acute stroke or TIA: atrial fibrillation, mitral stenosis, mechanical valve, intracardiac thrombus or vegetation, dilated cardiomyopathy or ejection fraction \\\u003C30%, proximal extracranial carotid or vertebral stenosis \\>50%.\n* Contraindications to MRI, including MR-incompatible metallic implants (i.e. certain artificial cardiac valves, penile implants, other prosthesis), implanted electronic devices (i.e. pacemaker\u002Fdefibrillator, neurostimulators, cochlear implants), other potentially mobile ferromagnetic material (i.e. shrapnel, magnetic aneurysm clips), pregnancy (women in fertile age should have a negative pregnancy test), lactation, morbid obesity, and severe claustrophobia.",true,"30 Years",{"count":292,"type":22},250,"An observational study to determine if individuals with increased platelet FcyRIIa will have a higher risk of ischemic events.",[95,295,26,296],"TIA","Ischemic",[95],"2026-06-09",{"date":252,"type":43},{"date":301,"type":43},"2022-09-30",{"date":303,"type":22},"2027-09-30",{"name":305,"class":80},"University of California, Los Angeles",{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":63,"phases":315,"briefSummary":317,"conditions":318,"keywords":320,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":137},"100642062","phase-4-platelet-aggregation-function-guided-de-escalation-antiplatelet-therapy-in-patients-with-acute-ischemic-stroke-100642062","NCT07644234","Platelet Aggregation Function-Guided De-Escalation Antiplatelet Therapy in Patients With Acute Ischemic Stroke","PATH STROKE D","Inclusion Criteria:\n\n* 1.Age 18 years or older. 2.Diagnosis of acute non-disabling ischemic stroke or transient ischemic attack according to World Health Organization criteria, meeting one of the following definitions: acute non-disabling ischemic stroke, defined as a National Institutes of Health Stroke Scale score of 5 or lower at enrollment; or high-risk transient ischemic attack, defined as an ABCD2 score of 4 or higher.\n\n  3.Symptom onset within 48 hours. Onset time is defined as the interval from the last time the participant was known to be well to the time of combined administration of clopidogrel 300 mg and aspirin 100 mg.\n\n  4.MARADP \\\u003C35% measured 5 to 20 hours after combined antiplatelet treatment with clopidogrel 300 mg and aspirin 100 mg within 48 hours of symptom onset.\n\n  5.Planned treatment with aspirin plus clopidogrel or clopidogrel monotherapy for antiplatelet therapy.\n\n  6.Written informed consent provided by the participant or a legally authorized representative.\n\nExclusion Criteria:1.Imaging evidence of hemorrhagic stroke, hemorrhagic transformation, or another pathological brain disorder, such as vascular malformation, tumor, abscess, or another common non-ischemic brain disease such as multiple sclerosis.\n\n2.Minor stroke or transient ischemic attack caused by angioplasty or vascular surgery.\n\n3.Atrial fibrillation indicated by standard electrocardiography or typical physical signs of atrial fibrillation, including absolutely irregular rhythm, variable intensity of the first heart sound, or pulse deficit.\n\n4.A clear indication for anticoagulation, including suspected cardioembolism such as atrial fibrillation, known artificial heart valve, or suspected endocarditis.\n\n5.Intravenous thrombolysis, intra-arterial thrombolysis, mechanical thrombectomy, or any revascularization procedure performed after the index event or planned within 90 days.\n\n6.Use of antiplatelet agents other than aspirin or clopidogrel within 7 days before enrollment, such as ticagrelor or prasugrel.\n\n7.History of gastrointestinal bleeding, intracranial hemorrhage, recent major bleeding or blood transfusion, excluding minor hemoptysis or minor abnormal vaginal bleeding, or other bleeding disorder caused by coagulation dysfunction, such as purpura.\n\n8.Contraindication or intolerance to clopidogrel or aspirin, including known allergy; severe hepatic insufficiency or renal insufficiency; severe heart failure; coagulation disorder or history of systemic bleeding; history of thrombocytopenia or neutropenia; or history of drug-induced hematologic disease or hepatic dysfunction.\n\n9.Leukopenia, defined as white blood cell count \\\u003C2 x 10\\^9\u002FL, or thrombocytopenia, defined as platelet count \\\u003C100 x 10\\^9\u002FL.\n\n10.Use of heparin or oral anticoagulants within 10 days before enrollment. 11.Severe cardiac, pulmonary, hepatic, or renal dysfunction, or severe comorbid disease such as tumor, chronic airflow disease, severe dementia, or severe heart failure.\n\n12.Female participants of childbearing potential with a negative pregnancy test who refuse to use effective contraception, or women who are pregnant or breastfeeding.\n\n13.Poor compliance or inability to complete study requirements.\n\n\\-",{"count":314,"type":22},3836,[316],"PHASE4","This multicenter, prospective, open-label, randomized controlled trial will evaluate whether platelet aggregation function-guided de-escalation of antiplatelet therapy is non-inferior in efficacy and superior in safety compared with standard dual antiplatelet therapy in patients with acute minor ischemic stroke or high-risk transient ischemic attack who are sensitive to clopidogrel.\n\nParticipants who present within 48 hours of symptom onset and meet the eligibility criteria will receive loading doses of clopidogrel and aspirin, followed by platelet aggregation function testing. Eligible clopidogrel-sensitive participants will be randomized to receive either 7 days of dual antiplatelet therapy followed by clopidogrel monotherapy or standard 21-day dual antiplatelet therapy followed by single antiplatelet therapy. The primary efficacy outcome is new stroke within 90 days after randomization.",[26,319],"Transient Ischemic Attack",[321,26,322,323],"Antiplatelet de-escalation","Platelet function tests","RCT","2026-06-08",{"date":208,"type":43},{"date":327,"type":22},"2026-06",{"date":329,"type":22},"2029-10",{"name":331,"class":80},"Sichuan Provincial People's Hospital",{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":339,"enrollmentInfo":340,"targetDuration":4,"studyType":63,"phases":341,"briefSummary":342,"conditions":343,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":347,"leadSponsor":348,"locationsCount":137},"100642618","transcranial-focused-ultrasound-neuromodulation-for-post-stroke-motor-dysfunction-100642618","NCT07637825","Transcranial Focused Ultrasound Neuromodulation for Post-Stroke Motor Dysfunction","Transcranial Focused Ultrasound Neuromodulation in Post-Stroke Motor Dysfunction","Inclusion Criteria:\n\n* (1) Patients with a confirmed imaging diagnosis of first-ever ischemic stroke; (2) Unilateral limb motor involvement; (3) Modified Ashworth Scale (MAS) grade ≤3 for the upper extremity, Brunnstrom stage II-V, and upper extremity Fugl-Meyer Assessment (FMA-UE) score between 15 and 60 (inclusive); (4) Age 18-75 years, onset within 21 days to 6 months, in the subacute or recovery phase; (5) Stable vital signs, no consciousness impairment, informed consent provided, ability to cooperate with clinical assessments, and approval obtained from the institutional ethics committee.\n\nExclusion Criteria:\n\n* (1) Contraindications to MRI; (2) Infarction involving the thalamus; (3) Risk of intracranial hemorrhage; (4) Presence of intracranial metallic foreign bodies, cardiac pacemakers, or cochlear implants; (5) Unstable medical condition, severe cognitive impairment or psychiatric disorders rendering the patient unable to comprehend the study or cooperate with assessments; (6) Conditions affecting limb motor function, including fractures, joint contractures, or severe limb spasticity; (7) Current use of medications that alter cortical excitability.","75 Years",{"count":198,"type":22},[92],"This study aims to evaluate how transcranial focused ultrasound (tFUS) technology can promote neural network remodeling and functional recovery after stroke. By integrating signals from electroencephalography (EEG) and magnetic resonance imaging (MRI), the study will investigate how activating or inhibiting specific brain regions affects motor and cognitive recovery. The goal is to improve patients' motor and cognitive functions, reduce long-term disability, and enhance quality of life. The study also seeks to optimize stimulation parameters to maximize rehabilitation outcomes and explore the mechanisms underlying neuroprotection and functional reconstruction after stroke.\n\nThis is a case-control study involving a total of 60 participants. Participants will be ischemic stroke survivors aged 18-75 years, with first-ever stroke onset between 21 days and 6 months, stable vital signs, no consciousness disorders, and the ability to provide informed consent and cooperate with assessments. Eligible participants must have unilateral limb motor impairment, with an upper extremity modified Ashworth score ≤3, Brunnstrom stage II-V, and an upper extremity Fugl-Meyer Assessment (FMA-UE) score between 15 and 60.\n\nParticipants will be assigned to either a neuromodulation group (receiving multi-modal neuromodulation targeting specific brain regions) or a control group (receiving sham stimulation or conventional treatment). Primary outcome measures include changes in FMA-UE scores, neuroimaging data (CT\u002FMRI), EEG measurements (resting-state and task-state spectral power, functional connectivity), and laboratory markers (complete blood count, CRP, IL-6, S100β, BDNF). Secondary outcome measures include Brunnstrom stage, Ashworth grade, muscle strength, and patient comfort ratings. Safety will be monitored through blood routine tests, blood biochemistry, and coagulation function.\n\nStatistical analysis will compare key indicator changes between the neuromodulation and control groups before and after intervention. Independent t-tests (for two groups) or ANOVA (for multiple groups) will be used to assess between-group differences, with non-parametric tests applied for data not following a normal distribution.",[26],"2026-06-05",{"date":274,"type":43},{"date":327,"type":22},{"date":134,"type":22},{"name":349,"class":80},"Jiangsu Taizhou People's Hospital",{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":356,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":358,"enrollmentInfo":359,"targetDuration":4,"studyType":63,"phases":361,"briefSummary":362,"conditions":363,"keywords":364,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":376},"100621167","a-pivotal-study-evaluating-safety-and-effectiveness-of-adaptative-tip-catheter-in-patients-with-acute-ischemic-stroke-100621167","NCT07367100","A Pivotal Study Evaluating Safety and Effectiveness of Adaptative Tip Catheter in Patients With Acute Ischemic Stroke","A Prospective, First in Human Pivotal Study to Evaluate the Adaptive Tip Catheter Used to Treat Acute Ischemic Stroke Patients During Mechanical Thrombectomy","PHAST","Inclusion criteria:\n\n* Age greater than or equal to (\\>=) 18 years, less than or equal to (\\\u003C=) 90 years, at the time of consent\n* Signs and symptoms consistent with the diagnosis of acute ischemic stroke in the anterior circulation that can be treated with endovascular thrombectomy approaches\n* Endovascular treatment can be initiated (defined as access puncture) within 24 hours from time last known well\n* Baseline National Institutes of Health Stroke Scale (NIHSS) score \\>= 6\n* Baseline Alberta Stroke Program Early CT Score (ASPECTS) \\>= 3\n* A signed and dated Informed Consent Form (ICF) or Investigator Statement for emergency procedure (as allowed according to country regulations and approved by EC) has been obtained\n\nExclusion criteria:\n\n* Known pregnancy, as evidenced by positive pregnancy test for women of childbearing potential or breast feeding\n* Life expectancy less than (\\\u003C) 90 days prior to stroke onset\n* Known hemorrhagic diathesis disorder, coagulation factor deficiency or oral anticoagulant therapy with known International Normalized Ratio (INR) greater than (\\>) 3.0\n* Clinical symptoms and\u002For CT\u002FMRI evidence suggestive of bilateral stroke or stroke in multiple vascular territories, defined as occlusions in more than one vessel not downstream from each other (for example, bilateral anterior circulation, anterior\u002Fposterior circulation)\n* Clinical history, past imaging or clinical judgement suggest that the intracranial occlusion is chronic\n* Computed Tomography\u002F Magnetic Resonance Imaging (CT\u002FMRI) evidence of recent\u002Ffresh hemorrhage\n* Baseline CT or MRI showing mass effect\n* Currently participating in an investigational (drug, device, etc.) clinical trial that may confound study endpoints. Patients in observational, natural history, and\u002For epidemiological studies not involving intervention are eligible\n* Cerebral catheter angiographic evidence of pre-existing arterial disease, that potentially impacts treatment and\u002For outcome (for example, vasculitis)\n* Any occlusion or stenosis that limits device access to the target area (for example, carotid dissection, tandem occlusions) or requiring acute stenting to achieve access\n* Cerebral catheter angiographic evidence of multiple cerebrovascular occlusions, defined as occlusions in more than one vessel not downstream from each other (for example, bilateral anterior circulation, anterior\u002Fposterior circulation)\n* Excessive vascular access tortuosity that will likely prevent endovascular access with the adaptive tip catheter (ATC)\n* Baseline expanded thrombolysis in cerebral infarction (eTICI) \\> 1","90 Years",{"count":360,"type":22},74,[92],"The purpose of this study is to assess the safety and the effectiveness of the Adaptive Tip Catheter (ATC) used as a first line direct aspiration thrombectomy technique for patients suffering of an acute ischemic stroke.",[26],[365,366,367],"Large Vessel Occlusion","Acute Ischemic Stroke","Mechanical Thrombectomy","2026-06-04",{"date":344,"type":43},{"date":371,"type":43},"2026-02-02",{"date":373,"type":22},"2027-07-31",{"name":375,"class":50},"Neuravi Limited",15,{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":63,"phases":387,"briefSummary":388,"conditions":389,"keywords":391,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":398,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":405},"100601520","phase-4-lacunar-stroke-hyperacute-clinical-utilization-of-novel-approach-regimens-rt-pa-vs-dapt-randomised-clinical-trial-100601520","NCT07111559","Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical Trial","A Multicenter Randomized Controlled Trial Comparing Tissue Plasminogen Activator With Dual Antiplatelet Therapy for Patients With Hyperacute Single Perforating Artery Infarction","LACUNAR-tPA","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Acute ischemic stroke within 4.5 hours from onset. If onset time is unknown because of impaired consciousness or aphasia, use the \"last known well\" time.\n* A single perforating-artery infarct on brain MRI:\n\nlocated in the corona radiata, putamen, internal capsule, thalamus, or pons; solitary, mainly round or oval, with a maximum diameter ≤ 20 mm; lesions only in the centrum semiovale are not allowed, but extension from the above sites into the centrum semiovale is allowed.\n\n* No disability in daily life before the stroke (modified Rankin Scale ≤ 1).\n* National Institutes of Health Stroke Scale (NIHSS) score ≤ 5.\n* Written informed consent obtained.\n\nExclusion Criteria:\n\n* Antithrombotic therapy considered inappropriate because of active bleeding, low platelet count, or similar conditions.\n* Any contraindication to intravenous rt-PA, without blood pressures.\n* ≥ 50 % stenosis or occlusion of the artery responsible for the stroke \\* (see note below).\n* Diseases that require anticoagulation (e.g., atrial fibrillation, deep-vein thrombosis) \\*\n* Inability to take medicine orally.\n* Any other reason judged by the principal investigator or co-investigators to make participation inappropriate.\n\nNote: This study targets hyper-acute stroke within 4.5 hours. To avoid treatment delay, items marked with \\* must be judged using the similar examinations that each site normally performs before rt-PA administration.",{"count":386,"type":22},500,[316],"The goal of this clinical trial is to learn if a combination of antiplatelet drugs works better than intravenous tissue plasminogen activator to treat small ischemic stroke (lacunar stroke). The main questions it aims to answer are:\n\nIs a combination of antiplatelet drugs non-inferior to the current standard tissue plasminogen activator treatment? Does a combination of antiplatelet drugs reduce the bleeding complications than tissue plasminogen activator?\n\nResearchers will compare a combination of antiplatelet drugs to tissue plasminogen activator to see if a combination of antiplatelet drugs works to treat small ischemic stroke (lacunar stroke).\n\nParticipants will:\n\nTake a combination of antiplatelet drugs or be given intravenous tissue plasminogen activator Check the neurological status 3 months after stroke, in-person, by phone, or by mail.",[390,95,26],"Lacunar Stroke",[392,393,394,395,396,397],"rt-PA","tissue-plasminogen activator","DAPT","dual antiplatelet therapy","minor stroke","lacunar stroke",{"date":344,"type":43},{"date":400,"type":43},"2025-08-01",{"date":402,"type":22},"2029-03-31",{"name":404,"class":80},"Nippon Medical School",28,{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":18,"minAge":413,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":63,"phases":416,"briefSummary":417,"conditions":418,"keywords":420,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":137},"100553492","phase-4-stroke-prevention-in-ischemic-stroke-with-covert-atrial-fibrillation-100553492","NCT06486792","Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation","SPICAF","Inclusion Criteria:\n\nIncluded patients must fulfill the following 4 criteria:\n\n1. patient aged ≥65 years with:\n\n   1. recent (\\\u003C15 days) cerebral infarction\n   2. with cerebral ischemia proven on MRI or head-CT\n2. with no known atrial fibrillation before stroke and no atrial fibrillation detected during hospital stay (monitoring or telemetry) and no mural thrombus.\n3. but with suspected atrial fibrillation:\n\n   1. multiple territorial (i.e., in the territory of a cerebral artery or one of its branches) cerebral infarctions in several arterial territories involving both hemispheres, or in the same hemisphere, or in both anterior and posterior circulation, symptomatic or not\n   2. or a single cerebral infarction and systemic emboli (e.g., renal, splenic, hepatic or mesenteric infarction, peripheral emboli in arm or leg), symptomatic or not\n   3. or any ischemic stroke with dilation of atrium (\\>34 mL\u002Fm²) or left atrial spontaneous echocardiographic contrast or LAA velocities \\\u003C 40 cm\u002Fsec or pro BNP \\> 400 pg\u002FmL or left ventricular ejection fraction (LVEF) \\\u003C 40% or supraventricular extrasystole ≥ 400\u002F24 h or longest \"atrial run\" ≥ 20 beats on telemetry\n   4. or age ≥80 year-old and a single infarction\n4. and a plan to detect atrial fibrillation with, long term Holter ECG, wearing device or implantable loop recorder\n5. with a Rankin score equal or less than 4\n6. patient has signed an informed consent\n7. Patient is affiliated to a social security.\n\nExclusion Criteria:\n\n1. Patients with a known cause of stroke, using ASCOD classification A1, C1, S1, O1, D1\n2. Symptomatic brain hemorrhage (the mere presence of microbleeds on gradient echo imaging is not an exclusion criteria)\n3. Uncontrolled hypertension (following the judgment of the investigator)\n4. Clear indication to anticoagulant or antiplatelet therapy\n5. Contra-indication to anticoagulant or antiplatelet therapy\n6. Intercurrent disease that may interfere with evaluation of the primary end-point or that may prevent follow-up study visits\n7. Participation in another interventional clinical trial.\n8. Under contraception in case of childbearing potential\n9. Patient under guardianship or curatorship","65 Years",{"count":415,"type":22},1148,[316],"Patients who have recently had an ischemic stroke with no clear cause might have undetected atrial fibrillation (AF) that isn't caught during their initial hospital stay. After discharge, these patients are typically monitored for AF using devices like Holter monitors or implantable loop recorders. Treatment options during this period include anticoagulants or aspirin. Anticoagulants are more effective in preventing recurrent strokes if AF is present, offering an 80% risk reduction compared to aspirin's 20%. If AF is detected, anticoagulant treatment continues; if not, patients may switch to aspirin after 6-12 months. Despite the clinical rationale for using anticoagulants during this search period, their benefit-risk ratio compared to aspirin has not been fully evaluated.",[95,26,419,151],"Cerebral Infarction",[95,26,421,151,422,423,424,425,426,427,428,429],"Cerebral infarction","Anticoagulant","Aspirin","Prevention stroke","AVK","Apixaban","rivaroxaban","dabigatran","ECG","2026-06-03",{"date":344,"type":43},{"date":433,"type":43},"2025-06-18",{"date":435,"type":22},"2028-12-18",{"name":437,"class":80},"Assistance Publique - Hôpitaux de Paris",{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":63,"phases":448,"briefSummary":449,"conditions":450,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":460},"100512139","phase-2-strategy-for-improving-stroke-treatment-response-100512139","NCT05948566","Strategy for Improving Stroke Treatment Response","Strategy for Improving Stroke Treatment Response (SISTER) Trial","SISTER","Inclusion Criteria:\n\n1. Age 18 years and older\n2. Suspected anterior circulation acute ischemic stroke\n3. NIH Stroke Scale score ≥4 prior to randomization\n\n   a. The participant must have a clearly disabling deficit if NIHSS is 4-5.\n4. Favorable baseline neuroimaging consisting of all of the following:\n\n   1. ASPECTS of 6 or more on CT (or ASPECTS of ≥7 on MRI)\n   2. Favorable perfusion imaging on CT perfusion (CTP)\u002FMR-perfusion weighted imaging (PWI) consisting of all of the following:\n\n   i. Mismatch ratio of penumbra: core \\>1.2 ii. Mismatch volume \\>10 cc iii. Core \\\u003C70 cc\n\n   c. If CT hypodensity is present, then in the investigator's visual assessment, the total acute infarct volume combined area of (a) the CT hypodensity and (b) the perfusion-based core volume (CBF\\\u003C30%) should be smaller than perfusion-based volume (area of Tmax\\>6s minus CBF\\\u003C30%).\n5. Able to receive assigned study drug within 4.5 to 24 hours of stroke onset or last known well.\n6. Able to receive assigned study drug within 120 minutes of qualifying perfusion imaging. \\*\n7. Informed consent for the study participation obtained from participant or their legally authorized representatives.\n\n   * Study drug administration is encouraged within 90 minutes after qualifying perfusion image but is allowed up to 120 minutes. After 120 minutes, another perfusion image to ensure that inclusion criteria are met is required.\n\nExclusion Criteria:\n\n1. Received endovascular treatment with clot engagement.\n\n   1. Patients who undergo groin puncture but clot engagement is not attempted due to spontaneous distal migration are permitted to be enrolled in the trial if all other eligibility criteria are met.\n   2. Patients who undergo groin puncture but clot is not engaged due to reasons other than spontaneous distal migration are NOT permitted.\n2. Received or planned to receive intravenous thrombolysis.\n3. Pre-stroke modified Rankin score \\>2.\n4. Previous treatment with TS23 or known previous allergy to antibody therapy.\n5. Known pregnancy, women who are breastfeeding or plan to breastfeed within 3 months of receiving TS23 or have a positive urine or serum pregnancy test for women of childbearing potential.\n6. Known previous stroke in the past 90 days.\n7. Known previous intracranial hemorrhage, intracranial neoplasm, subarachnoid hemorrhage, or arterial venous malformation.\n8. Known active diagnosis of intracranial neoplasm.\n9. Clinical presentation suggestive of a subarachnoid hemorrhage, even if initial CT scan was normal.\n10. Surgery or biopsy of parenchymal organ in the past 30 days.\n11. Known trauma with internal injuries or persistent ulcerative wounds in the past 30 days.\n12. Severe head trauma in the past 90 days.\n13. Persistent systolic blood pressure \\>180mmHg or diastolic blood pressure \\>105mmHg despite best medical management.\n14. Serious systemic hemorrhage in the past 30 days.\n15. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with International Normalized Ratio (INR) \\>1.7.\n16. Platelets \\\u003C100,000\u002Fmm3.\n17. Hematocrit \\\u003C25 %.\n18. Elevated aPTT above laboratory upper limit of normal.\n19. Creatinine \\> 4 mg\u002Fdl, or patients receiving renal dialysis, regardless of creatinine.\n20. Received the following within the previous 24 hours:\n\n    1. If patient received unfractionated heparin within the last 24 hours, the patient must have an aPTT within normal range prior to enrollment.\n    2. Low molecular weight heparins such as Dalteparin, enoxaparin, tinzaparin in full dose within the previous 24 hours.\n21. Received Factor Xa inhibitors (such as Fondaparinux, apixaban or rivaroxaban) within the past 48 hours.\n22. Received direct thrombin inhibitors (e.g., argatroban, dabigatran, bivalirudin, desirudin, lepirudin) within 48 hours.\n23. Received glycoprotein IIb\u002FIIIa inhibitors within the past 14 days.\n24. Known pre-existing neurological or psychiatric disease which would confound the neurological\u002Ffunctional evaluations.\n25. Current participation in another research drug treatment protocol (i.e., participants could not start another experimental agent until after 90 days).\n26. Concurrent acute myocardial infarction, pulmonary embolism, deep venous thrombosis or other thrombotic event that requires anticoagulation or anti-platelet treatment.",{"count":447,"type":22},300,[65],"SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.",[26],"2026-06-01",{"date":453,"type":43},"2026-06-02",{"date":455,"type":43},"2024-03-18",{"date":457,"type":22},"2027-12",{"name":459,"class":50},"Translational Sciences, Inc.",52,{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":63,"phases":471,"briefSummary":472,"conditions":473,"keywords":479,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":497},"100641032","effectiveness-of-best-care-practices-in-acute-stroke-in-conventional-hospitalization-best-care-ictushc-100641032","NCT07627399","Effectiveness of Best Care Practices in Acute Stroke in Conventional Hospitalization (BEST CARE ICTUS_HC)","Effectiveness of Implementing Best Care Practices in the Management of Patients With Acute Stroke in Conventional Hospitalization: A Cluster-Randomized, Open, Stepped-Wedge Controlled Trial.","BESTCAREICTUS","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Clinical diagnosis of acute ischemic or hemorrhagic stroke.\n* Admission to conventional hospitalization units (Internal Medicine) in regional hospitals without specialized Stroke Units.\n\nExclusion Criteria:\n\n* Patients admitted for a cause other than stroke who develop a stroke during their hospital stay (in-hospital stroke).\n* Patients subjected to invasive neurological procedures.\n* Patients undergoing invasive procedures, such as thrombectomy, who require transfer to a referral hospital and remain there for more than 48 hours.\n* Patients with deterioration of the level of consciousness that prevents the performance of dysphagia testing.\n* Patients that have been taken care of by Nurses and Nursing Assistants with \\>4 weeks of work experience in Stroke Units in the last 12 months",{"count":470,"type":22},700,[92],"The goal of this clinical trial is to evaluate whether a multicomponent nurse-led intervention (BEST CARE ICTUS\\_HC) can reduce stroke-related complications and improve recovery in adults (18 years and older) hospitalized with an acute ischemic or hemorrhagic stroke in hospitals without specialized Stroke Units. The main questions it aims to answer are:\n\n1. Does the implementation of the program increase the early and correct detection of swallowing difficulties (dysphagia) to prevent pneumonia?\n2. Does the program reduce the severity of attention problems (hemineglect) and improve the patients' quality of life up to 6 months after discharge?\n\nResearchers will compare patients receiving the BEST CARE ICTUS\\_HC program to patients receiving usual hospital care to see if this new approach improves patient safety and long-term functional recovery.\n\nParticipants will:\n\n* Receive either the usual hospital care for stroke or the BEST CARE ICTUS\\_HC nursing program, depending on the study phase of the hospital.\n* Be screened for swallowing problems using a standardized test before receiving any food or drink.\n* Be cared for in an adapted environment (FLECHA Project) that uses visual signs and room organization to help with orientation and safety.\n* Have their temperature, blood sugar, and blood pressure monitored under a strict specialized protocol.\n* Be contacted by phone 30 days and 6 months after leaving the hospital to answer questions about their health and quality of life.",[95,27,26,96,474,475,476,477,478],"Cerebrovascular Disorders","Deglutition Disorders","Perceptual Disorders","Unilateral Neglect","Pneumonia, Aspiration",[27,480,481,477,482,483,484,485,486,487,488],"Nursing Care","Dysphagia Screening","Multicomponent Intervention","Care Bundle","Stepped-Wedge Design","Deglutition","Quality of life","Hyperglycemia","Fever","2026-05-29",{"date":368,"type":43},{"date":492,"type":43},"2026-05-12",{"date":494,"type":22},"2028-12",{"name":496,"class":80},"University of Malaga",4,{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":502,"acronym":503,"eligibilityCriteria":504,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":505,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":507,"conditions":508,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":137},"100639950","recovery-trajectory-for-coma-and-disorders-of-consciousness-100639950","NCT07614074","Recovery Trajectory for Coma and Disorders of Consciousness","Coma Cohort","Inclusion Criteria:\n\n* Age greater than or equal to 18 years on the day of hospital admission\n* Coma duration of at least 24 hours from presentation to the receiving hospital, or died prior to the 24 hour timepoint without return of consciousness. Coma defined as: GCS score of less than or equal to 10 AND GCS score of less than 6 on the motor component of the GCS(not following commands) AND GCS score less than 3 on the verbal component AND alteration of consciousness not explained by sedation only\n* Coma due to a neurological process (Including but not limited to: trauma, stroke, hypoxic- ischemic brain injury (HIBI), CNS infection, seizure, other processes at the discretion of the investigator)\n* Admission to the intensive care unit, or deceased prior to admission.\n\nExclusion Criteria:\n\n* Pre-existing score of 5 or less on the motor component of the Glasgow Coma Scale prior to hospital admission.\n* Transfer from another acute care hospital in which the motor component of the Glasgow Coma Scale on the day after initial hospital arrival is not known or cannot be reconstructed from medical records or history.\n* Coma due to sepsis, systemic metabolic processes (ex: organ failure or sedation).\n* GCS score of greater than 2 for eye opening with lack of command following due to a focal brain lesion causing receptive aphasia.\n* Prisoner",{"count":506,"type":22},2000,"This study aims to better understand recovery after coma caused by serious neurologic illness or injury. Patients who are unconscious (in a coma or disorder of consciousness) due to conditions such as stroke, cardiac arrest, traumatic brain injury, seizures, brain infection, or other neurologic emergencies may be enrolled during their hospitalization.\n\nThe purpose of this observational research study is to learn which medical, neurologic, psychological, and social factors are associated with recovery over time. Researchers will collect information from the medical record during hospitalization, including details about the patient's illness, treatments received, brain imaging, and neurologic examinations.\n\nFor patients who survive hospitalization, the study team will contact participants or their caregivers after discharge to assess recovery at scheduled time points using questionnaires and structured interviews about physical function, quality of life, emotional well-being, and daily activities.\n\nThis study does not assign participants to any experimental treatment. Participation will not change the medical care patients receive. Information learned from this study may help improve future care for patients with coma and disorders of consciousness.",[509,510,511,512,26,513,514,515],"Coma","Disorders of Consciousness","Cardiac Arrest (CA)","Traumatic Brain Injuries","Hemorrhagic Stroke, Intracerebral","Meningitis\u002FEncephalitis","Status Epilepticus","2026-05-28",{"date":453,"type":43},{"date":519,"type":43},"2023-09-26",{"date":521,"type":22},"2033-09",{"name":523,"class":80},"University of California, San Francisco",{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":530,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":532,"targetDuration":4,"studyType":63,"phases":534,"briefSummary":535,"conditions":536,"keywords":541,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":405},"100518226","ctsn-embolic-protection-trial-100518226","NCT06027788","CTSN Embolic Protection Trial","Embolic Protection in Patients Undergoing High-Risk Valve Surgery","EMPRO","Inclusion Criteria:\n\n* Age ≥ 60 years\n* Planned de novo or redo:\n\n  * Surgical aortic valve replacement SAVR ± ascending aortic repair (if circulatory arrest is not required) ± CABG\n  * Mitral valve replacement (MVR) ± CABG\n  * Mitral Valve Repair + CABG,\n  * Double\u002FTriple valve surgery ± CABG; Ross procedure These procedures can be done via a full or minimal-access sternotomy (using central aortic perfusion cannulae) with legally marketed valve(s), and can be done in combination with an left atrial appendage (LAA) closure\u002Fexcision or partial\u002Fcomplete Maze procedure.\n  * Valve sparing aortic root replacement (David procedure)\n  * Valve sparing aortic root replacement (David procedure)\n* No evidence of neurological impairment as defined by a NIHSS ≤1 and modified Rankin scale (mRS) ≤2 within 30 days prior to randomization\n* Ability to provide informed consent and comply with the protocol\n\nExclusion Criteria:\n\n* History of clinical stroke within 3 months prior to randomization\n* Cerebral and or aortic arch arteriography or interventions within 3 days of the planned procedure\n* Coronary catheterization within 3 days of index procedure, and the required repeat NIHSS score post-catheterization is worse than the screening\u002Fbaseline NIHSS score conducted prior to the catheterization\n* Active endocarditis at time of randomization with vegetation criteria\n* Clinical signs of cardiogenic shock or treatment with IV inotropic therapy prior to randomization\n* Participation in an interventional (drug or device) trial\n* Isolated mitral valve repair, isolated tricuspid valve repair or combined mitral valve repair and tricuspid valve repair\n* Anticipated requirement for prolonged mechanical ventilation greater than 48 hours after surgery in the opinion of the investigator\n* Planned concomitant carotid endarterectomy during index surgical procedure",{"count":533,"type":22},842,[92],"This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.",[537,26,538,539,540],"Delirium","Acute Kidney Injury","Heart Valve Disease","Coronary Artery Disease",[542,543,544],"Embolic Protection","Cardiac Surgery","CardioGard","2026-05-26",{"date":489,"type":43},{"date":548,"type":43},"2023-09-18",{"date":550,"type":22},"2027-04-01",{"name":552,"class":80},"Icahn School of Medicine at Mount Sinai",{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":4,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":560,"enrollmentInfo":561,"targetDuration":4,"studyType":63,"phases":563,"briefSummary":564,"conditions":565,"keywords":568,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":582},"100624830","testing-the-effectiveness-of-a-novel-intervention-to-improve-medication-adherence-in-stroke-survivors-100624830","NCT07414732","Testing the Effectiveness of a Novel Intervention to Improve Medication Adherence in Stroke Survivors","The \"Savvy for Stroke Survivors\" Study: Testing a Novel Tool to Help Stroke Survivors Take Their Medication","Inclusion criteria:\n\n1. Participants must be between the ages of 18 years old and 99 years old at the time of consent.\n2. Self-reported primary diagnosis of stroke (ischemic or hemorrhagic) within the past 12 months, without structural, traumatic or secondary causes (including aneurysm, arteriovenous malformation, or tumor).\n3. Currently prescribed an antihypertensive regimen.\n4. Currently less than optimal adherence to medication, defined as a score \\\u003C25 on the Medication Adherence Report Scale (MARS-5).\n5. Cognitively able to manage medications independently, defined as a score of \\>4 on the Six-Item Screener (SIS) for cognitive impairment.\n6. Speaks English sufficiently to complete consent and study procedures.\n7. Has access to a phone that can receive text messages and is able to participate in scheduled phone-based follow-up assessments.\n8. Uses, or willing to start using, a single pharmacy chain for prescription refills and is willing to provide consent for the study team to contact the pharmacy to retrieve prescription refill data.\n9. Willing and able to provide informed consent.\n\nExclusion criteria:\n\n1. Prescribed a more than three scheduled daily medication doses.\n2. Prescribed a complex medication regimen requiring more than five additional oral medications per dose time.\n3. Diagnosed with secondary hypertension or other BP conditions not managed with standard oral antihypertensives.\n4. Has upper extremity impairments or other physical limitations that prevent safe use of the medication box or BP monitor.\n5. Lives in an environment where the medication organizer cannot be safely or consistently accessed, such as in temporary housing, shelters, or unstable living conditions.\n6. Diagnosed with moderate-to-severe cognitive impairment, dementia, or active psychiatric instability that precludes informed consent or reliable participation.\n7. Known allergy or contraindication to the materials used in the BP monitor or the medication box.\n8. Participation in another intervention trial targeting medication adherence or BP control.\n9. Planned relocation or anticipated unavailability for the 12-month study period.","99 Years",{"count":562,"type":22},150,[92],"The goal of this study is to test if Savvy, a multimodal intervention (consisting of psychological exercises, a weekly pill organizer, and a text message reminder system) can improve medication adherence in stroke survivors.\n\nThe main questions it aims to answer are:\n\n* Can the Savvy tool improve medication adherence in stroke survivors compared to usual care?\n* Does the use of the Savvy tool lead to better blood pressure control after a stroke?\n\nThe investigators will compare the use of the Savvy intervention to a control group that receives usual care, including a package of educational materials.\n\nThe study consists of the following components:\n\n* Participants will receive the Savvy intervention or usual care. The intervention package consists of short psychological exercises over the phone, a weekly medication organizer to support daily medication intake, and text message reminders to take medication and refill the medication box. Participants in the control group will receive usual care, including educational materials about the importance of blood pressure and medication.\n* All participants will receive a free home blood pressure monitor and will be requested to measure their blood pressure at certain time points during the study.\n* Participants will be enrolled in the study for 6 months and will have virtual follow-up calls at 3 and 6 months.",[95,566,26,567],"Intracerebral Haemorrhage","TIA (Transient Ischemic Attack)",[569,570,571,95,572],"Medication Adherence","Motivational Interviewing (MI)","Blood pressure","Secondary Prevention","2026-05-19",{"date":575,"type":43},"2026-05-20",{"date":577,"type":43},"2026-03-31",{"date":579,"type":22},"2027-04-30",{"name":581,"class":80},"Massachusetts General Hospital",2,{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":4,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":196,"enrollmentInfo":590,"targetDuration":4,"studyType":63,"phases":592,"briefSummary":593,"conditions":594,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":137},"100602743","hemoadsorption-for-severe-ischemic-stroke-100602743","NCT07127484","Hemoadsorption for Severe Ischemic Stroke","Efficacy and Safety of Hemoadsorption for Severe Ischemic Stroke","Inclusion Criteria:\n\n1.18 years ≤ age \\\u003C 80 years; 2.Pre-stroke mRS score ≤ 1; 3.Anterior circulation cerebral infarction within 48 hours of onset, meeting at least one of the following:\n\n1. 15≤ NIHSS score ≤32;\n2. 3\\\u003CGCS score ≤12;\n3. CT hypodensity area \\>1\u002F2 of the MCA territory; 4.hs-CRP ≥2 mg\u002FL at randomization; 5.If reperfusion therapy is performed, no improvement in NIHSS score (still ≤32) post-treatment; 6.Signed informed consent obtained.\n\nExclusion Criteria:\n\n1. Hemorrhagic transformation of PH2 type prior to randomization;\n2. Brain herniation or decompressive craniectomy performed before randomization;\n3. Hemodynamic instability refractory to medical correction (systolic blood pressure \\\u003C70 mmHg or diastolic blood pressure \\\u003C50 mmHg) or decompensated heart failure (NYHA Class III or IV);\n4. Severe hepatic impairment (defined as ALT \\>2 times the upper limit of normal or AST \\>2 times the upper limit of normal) and renal impairment (defined as serum creatinine \\>1.5 times the upper limit of normal or estimated glomerular filtration rate \\[eGFR\\] \\\u003C50 mL\u002Fmin);\n5. Coagulopathy or thrombocytopenia (platelet count \\\u003C100×10⁹\u002FL);\n6. Deep vein thrombosis (DVT) of the lower extremities before randomization;\n7. Life expectancy \\\u003C90 days due to malignancy;\n8. Participation in another drug or device clinical trial within the past 30 days or ongoing enrollment in such trials;\n9. Women of childbearing potential with a negative pregnancy test who refuse to use effective contraception, or pregnant\u002Flactating women;\n10. Absolute contraindications to hemoadsorption therapy.",{"count":591,"type":22},116,[92],"This is a multicenter, randomized-controlled, open-label, blinded endpoint clinical trial that aims to evaluate the efficacy and safety of hemoadsorption for severe ischemic stroke",[26,595],"Hemoadsorption","2026-05-13",{"date":598,"type":43},"2026-05-15",{"date":600,"type":43},"2026-01-05",{"date":602,"type":22},"2027-02-28",{"name":604,"class":80},"First Affiliated Hospital of Wannan Medical College",{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":611,"eligibilityCriteria":612,"healthyVolunteers":12,"sex":18,"minAge":290,"maxAge":196,"enrollmentInfo":613,"targetDuration":615,"studyType":23,"phases":4,"briefSummary":616,"conditions":617,"keywords":620,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":627,"leadSponsor":629,"locationsCount":137},"100639542","whole-life-investigation-of-lishui-longevity-100639542","NCT07592962","Whole-life Investigation of Lishui Longevity","Whole-life Investigation of Lishui Longevity Cohort Study","WILL","Inclusion Criteria:\n\n* Aged 30 to 80 years old; male-to-female ratio of 1:1; permanent residents in Lishui City; physically healthy; voluntary participation in the project with signed informed consent.\n\nExclusion Criteria:\n\n* Individuals ever diagnosed with malignant tumors or cardiovascular and cerebrovascular diseases by physicians or other health professionals; those with unstable vital signs or an expected survival time of less than 3 months; participants with incomplete basic information, and those unable to cooperate with subsequent follow-up.",{"count":614,"type":22},4500,"10 Years","1. To establish a standardized, normalized and scientific joint screening and follow-up management system for chronic disease multimorbidity in Lishui City, and early identify common risk factors of major chronic diseases such as cardiovascular and cerebrovascular diseases and tumors.\n2. To carry out targeted intervention and long-term follow-up for high-risk populations, reduce the incidence risk of major chronic diseases in the target population, improve residents' health status and grassroots comprehensive prevention and treatment capacity of chronic diseases, and provide scientific evidence and practical support for the construction of Healthy Lishui.",[26,618,619],"Chronic Disease","Cardiovascular",[621,622,623],"acute ischemic stroke","carotid artery stenosis","Hepatic fibrosis",{"date":625,"type":43},"2026-05-18",{"date":625,"type":22},{"date":628,"type":22},"2036-05-31",{"name":630,"class":80},"The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital",{"id":632,"slug":633,"hasResults":12,"nctId":634,"briefTitle":635,"officialTitle":636,"acronym":637,"eligibilityCriteria":638,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":196,"enrollmentInfo":639,"targetDuration":4,"studyType":63,"phases":640,"briefSummary":641,"conditions":642,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":644,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":649,"locationsCount":137},"100636508","measuring-absolute-brain-flow-and-brain-microcirculation-resistance-by-continuous-thermodilution-100636508","NCT07566598","Measuring Absolute Brain Flow and Brain Microcirculation Resistance by Continuous Thermodilution","Measuring Absolute Brain Flow and Brain Microcirculation Resistance by Continuous Thermodilution: a Pilot Study - RESISTANCE","RESISTANCE","Inclusion Criteria:\n\n* Men or women aged 18 to 80\n* Social Security beneficiaries\n* Obtained signed consent to participate in the study\n* TICI 2c or TICI 3 score after mechanical thrombectomy\n* Patients hospitalized for ischemic stroke due to middle cerebral artery thrombosis\n\nExclusion Criteria:\n\n* Spasm of an artery without significant stenosis\n* Vessel diameter less than 1 mm\n* Severe visceral failure\n* Local infection\n* Minors\n* Adults protected by law\n* Patients deprived of their liberty\n* Subjects who are uncooperative or unable to meet the requirements of the protocol\n* Subjects participating in another clinical trial or in a period of exclusion from a previous clinical trial\n* Pregnant women",{"count":376,"type":22},[92],"Worldwide, cerebrovascular accidents (also known as strokes) are the leading cause of acquired disability, the second-leading cause of dementia (after Alzheimer's disease) and the second-leading cause of death (but the leading cause of death among women). A mechanical thrombectomy (MT) allows the recanalization of the occluded cerebral artery during an acute ischemic stroke, by removing the blood clot with a mechanical device inserted endovascularly under image guidance. MTs are the optimal treatment for a large number of patients presenting an occlusion in an anterior artery (the internal carotid artery and the proximal segment of the middle cerebral artery). Reperfusion is considered satisfactory if the mTICI score at the end of the procedure is of mTICI 2c or mTICI 3. Despite these scores having been obtained by 71% of patients during the randomized trials, showing the superiority of MT over intravenous thrombolysis, only 27% of these patients were free of neurological deficits at 3 months . Therefore, there is a discrepancy between the high rate of macroscopic recanalization and clinical results. One hypothesis to explain this discrepancy is that despite high quality macroscopic recanalization, reperfusion of the cerebral microcirculation remains insufficient: macroscopic recanalization is not equivalent to microscopic reperfusion. This discrepancy also exists in cardiology: despite a high rate of coronary artery recanalization when patients with an ST- segment elevation myocardial infarction are in emergency care, half of these patients later exhibit coronary microvascular dysfunction. The absence of reperfusion is associated with an increased risk of cardiovascular death, recurring myocardial infarctions, cardiogenic shock and heart failure one year after the coronary recanalization for an ST-segment elevation myocardial infarction. It has been shown that continuous intracoronary thermodilution can be used to quantify coronary blood flow and the absolute value of microcirculatory resistance (in Wood units). There are not currently any tools that can quantify cerebral microcirculation immediately after an MT.\n\nThe aim of this study is to evaluate the feasibility and safety of using a pressure\u002Ftemperature sensing guidewire to measure cerebral microcirculatory resistance using thermodilution in patients with a score of mTICI 2c or 3 after MT for the management of acute ischemic stroke in the anterior circulation.",[26],"2026-05-11",{"date":596,"type":43},{"date":646,"type":43},"2026-04-07",{"date":648,"type":22},"2027-11",{"name":650,"class":80},"Centre Hospitalier Universitaire de Nice",{"id":652,"slug":653,"hasResults":12,"nctId":654,"briefTitle":655,"officialTitle":656,"acronym":4,"eligibilityCriteria":657,"healthyVolunteers":289,"sex":18,"minAge":19,"maxAge":358,"enrollmentInfo":658,"targetDuration":4,"studyType":63,"phases":660,"briefSummary":661,"conditions":662,"keywords":663,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":673,"lastUpdatePostDateStruct":674,"startDateStruct":675,"completionDateStruct":677,"leadSponsor":679,"locationsCount":681},"100640302","phase-4-mexidol-safety-and-efficacy-in-treatment-of-hyperacute-and-acute-ischemic-stroke-100640302","NCT07575984","Mexidol® Safety and Efficacy in Treatment of Hyperacute and Acute Ischemic Stroke","A Pilot, Randomized, Multicenter, Comparative, Open-label Study to Evaluate the Clinical, Laboratory, and Instrumental Efficacy and Safety of Mexidol® Solution for Intravenous and Intramuscular Administration, 50 mg\u002FmL (LLC RPC \"PHARMASOFT\", Russia), and Mexidol® FORTE 250 Film-coated Tablets, 250 mg (LLC RPC \"PHARMASOFT\", Russia), in the Treatment of Ischemic Stroke in Hyperacute and Acute Periods","Inclusion Criteria for Patients:\n\n1. Signed and dated Informed Consent Form (ICF) by the patient or their legal representative (in case of physical inability to sign), and\u002For a Decision of the Medical Board.\n2. Men and women aged 18 to 90 years (inclusive) at the time of signing the ICF or Decision of the Medical Board.\n3. First-ever hemispheric ischemic stroke (ICD-10 codes: I63.0-I63.9), confirmed by neuroimaging (CT or MRI).\n4. Presence of occlusion in the internal carotid artery (ICA) system at any level, including the middle cerebral artery (MCA) and anterior cerebral artery (ACA) (anterior circulation) and\u002For presence of neuroimaging signs, characteristic of acute cerebral ischemia (based on CT perfusion and\u002For MRI data in accordance with current Clinical Guidelines). Note: Presence of internal carotid artery (ICA) occlusion is not a mandatory criterion; neuroimaging signs of acute cerebral ischemia (CT perfusion\u002FMRI) are sufficient for inclusion.\n5. Time from the onset of acute ischemic stroke symptoms or the time the patient was last known to be well (last known well, LKW) to randomization is no more than 36 hours.\n6. No significant pre-stroke disability (the patient is able to carry out all daily activities and duties without assistance, a score of 0-1 on the modified Rankin Scale (mRS)).\n7. Total National Institutes of Health Stroke Scale (NIHSS) score of 6 to 20 (inclusive) at screening, provided that the score for item 5a\u002Fb (Motor Arm: Left\u002FRight) is at least 2 points on the paretic side and\u002For item 6a\u002Fb (Motor Leg: Left\u002FRight) is at least 2 points on the paretic side.\n8. 8\\. Agreement to use highly effective methods of contraception throughout the study and for 3 weeks after study completion. Eligible participants include: women of childbearing potential, who must have a negative pregnancy test and agree to use the following contraceptive methods: a barrier method (condom or occlusive cap \\[diaphragm or cervical\u002Fvault cap\\]) or a double-barrier method (condom or occlusive cap \\[diaphragm or cervical\u002Fvault cap\\] plus spermicide \\[foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository\\]); women of non-childbearing potential with documented history of hysterectomy, tubal ligation, infertility, or postmenopausal status (at least 1 year of amenorrhea); fertile men who must agree to use barrier contraception; men with documented infertility or prior vasectomy.\n\nInclusion Criteria for Healthy Volunteers:\n\n1. White male and female participants aged 18 to 45 years inclusive at the time of signing the Informed Consent Form (ICF).\n2. Verified \"healthy\" status based on standard clinical, laboratory, and instrumental examination methods.\n3. Ability to provide written informed consent prior to any screening procedures, and the ability, in the investigator's opinion, to comply with all study protocol requirements.\n4. Hemodynamic parameters: systolic blood pressure (SBP) within 100-130 mmHg, diastolic blood pressure (DBP) within 60-90 mmHg, heart rate (HR) 60-90 bpm, and respiratory rate (RR) 16-20 breaths per minute.\n5. Body Mass Index (BMI) from 18.5 to 30 kg\u002Fm² inclusive.\n6. Willingness to abstain from alcohol throughout the entire study period.\n7. Agreement to use highly effective methods of contraception throughout the entire study. Eligible participants include:\n\nwomen of childbearing potential, who must have a negative pregnancy test and agree to use the following contraceptive methods: a barrier method (condom or occlusive cap \\[diaphragm or cervical\u002Fvault cap\\]) or a double-barrier method (condom or occlusive cap \\[diaphragm or cervical\u002Fvault cap\\] plus spermicide \\[foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository\\]); women of non-childbearing potential with documented history of hysterectomy, tubal ligation, infertility, or postmenopausal status (at least 1 year of amenorrhea); fertile men who must agree to use barrier contraception; men with documented infertility or prior vasectomy.\n\nExclusion Criteria for Patients:\n\n1. Hypersensitivity to ethylmethylhydroxypyridine succinate or any other components of the investigational product.\n2. Galactose intolerance, lactase deficiency, or glucose-galactose malabsorption.\n3. Inability to take oral medications.\n4. Contraindications or inability to undergo CT\u002FMRI procedures (including, but not limited to: permanent cardiac pacemakers\u002Fneurostimulators; inner ear prosthesis, ferromagnetic or electronic middle ear implants, hemostatic clips, cardiac valve prostheses, or any other metal-containing structures; ferromagnetic fragments; insulin pumps; severe claustrophobia).\n5. Inability to undergo contrast-enhanced imaging for any reason.\n6. Patients who have received or are scheduled to receive thrombolytic therapy or thrombectomy for the current episode of ischemic stroke.\n7. Recurrent ischemic stroke.\n8. Direct signs of irreversible total occlusion of the internal carotid artery (ICA) system at the relevant level within the current episode of ischemic stroke (based on CT\u002FMRI data).\n9. Absence of neuroimaging signs of acute ischemic brain injury.\n10. Presence of any of the following neuroimaging (CT\u002FMRI) findings:\n\n    * Intracranial hemorrhage;\n    * Hemorrhagic transformation of the cerebral infarction;\n    * Subarachnoid hemorrhage;\n    * Brain tumor;\n    * Arteriovenous malformation (AVM);\n    * Brain abscess;\n    * Cerebral aneurysm;\n    * Edema of the infarct zone leading to brain structure displacement (malignant cerebral infarction).\n11. Lesion in the vertebrobasilar system.\n12. Any suspicion of subarachnoid hemorrhage (SAH) in the medical history or at the time of screening.\n13. History of hemorrhagic stroke or stroke of unspecified nature.\n14. Any known history of conditions associated with a bleeding tendency.\n15. Deep vein thrombosis (DVT) or pulmonary embolism (PE), or detection of a floating thrombus.\n16. Traumatic brain injury (TBI) within 6 months prior to screening.\n17. History of brain or spinal cord surgery within 5 years prior to study enrollment.\n18. Need for surgical intervention during participation in the clinical study.\n19. History of epilepsy.\n20. History of severe cognitive impairment, including dementia.\n21. Parkinson's disease.\n22. History of hereditary degenerative diseases of the Central Nervous System (CNS).\n23. History of demyelinating diseases of the nervous system.\n24. History of severe or global aphasia and\u002For clinical evidence of these conditions at screening.\n25. Myocardial infarction within 3 months prior to screening.\n26. NYHA Class III-IV chronic heart failure at the time of screening.\n27. Unstable angina pectoris at the time of screening.\n28. SBP ≥ 200 mmHg and\u002For DBP ≥ 100 mmHg at the time of screening.\n29. History of Stage III-IV Chronic Obstructive Pulmonary Disease (COPD).\n30. Uncontrolled diabetes mellitus.\n31. Renal impairment (creatinine clearance \\\u003C 50 mL\u002Fmin calculated by the Cockcroft-Gault formula) at the time of screening.\n32. Hepatic impairment (AST and\u002For ALT ≥ 2 × ULN and\u002For total bilirubin ≥ 1.5 × ULN) at the time of screening.\n33. History of HIV, syphilis, hepatitis B, and\u002For hepatitis C.\n34. Acute infectious diseases (influenza, upper respiratory tract infections, etc.) within 4 weeks prior to screening.\n35. Use of prohibited medications or other drugs that, in the investigator's opinion, may interfere with the study results within 30 days prior to screening, or the anticipated need for such medications during the patient's participation in the study.\n36. Use of medications based on ethylmethylhydroxypyridine succinate for 3 or more consecutive days within 2 weeks prior to randomization.\n37. Systemic autoimmune diseases or vascular collagenoses requiring prior or current treatment with systemic corticosteroids, cytostatics, or other immunosuppressants.\n38. History of malignant neoplasms, except for patients who have been disease-free for the past 5 years, or those with completely cured basal cell carcinoma of the skin, or completely cured carcinoma in situ.\n39. Other severe, decompensated, or unstable medical conditions that, in the investigator's opinion, are life-threatening, adversely affect the patient's prognosis, or preclude safe participation in the study.\n40. Life expectancy of less than 6 months.\n41. Unwillingness or inability of the patient to comply with the study protocol procedures (in the investigator's opinion).\n42. Pregnancy or breastfeeding (for women).\n43. History of alcoholism, drug addiction, or substance abuse and\u002For presence of these conditions at screening.\n44. History of schizophrenia, schizoaffective disorder, bipolar disorder, or other psychiatric disorders.\n45. Participation in another clinical trial within 3 months prior to study enrollment.\n46. Any other conditions that, in the investigator's opinion, preclude the patient's inclusion in the study.\n\nExclusion Criteria for Healthy Volunteers:\n\n1. Acute or chronic diseases of the cardiovascular, bronchopulmonary, endocrine, and nervous systems, including organic central nervous system (CNS) disorders, as well as gastrointestinal (GI), hepatic, renal, and hematological diseases.\n2. Galactose intolerance, lactase deficiency, or glucose-galactose malabsorption.\n3. Any deviations from normal values during laboratory and\u002For instrumental examinations.\n4. Inability to undergo blood sampling (e.g., due to compromised skin integrity at venipuncture sites).\n5. History of intracranial hemorrhage of any etiology.\n6. Hemophilia or other blood clotting disorders (including hypocoagulation states) and hemorrhagic diatheses.\n7. Active bleeding of any etiology at the time of screening.\n8. Decreased circulating blood volume (due to a salt-free diet, vomiting, or diarrhea).\n9. Blood donation or blood loss (≥ 450 mL of blood or plasma) within 3 months prior to screening.\n10. Any surgical procedures performed within 30 days prior to screening or planned during the study period.\n11. Acute infectious diseases, as well as fungal infections, within 4 weeks prior to the start of screening.\n12. Vaccination planned during the study or administered within 14 days prior to the start of screening.\n13. Regular use of medications, including herbal and homeopathic remedies, vitamins, and\u002For dietary supplements, within 4 weeks prior to the start of screening.\n14. Alcohol consumption within 72 hours prior to the start of screening.\n15. Use of medications with a significant effect on hemodynamics and\u002For liver function (e.g., barbiturates, omeprazole, cimetidine, etc.), injectable or oral hormonal contraceptives, subcutaneous hormonal implants, or intrauterine systems within 2 months prior to screening procedures.\n16. Adherence to a specific diet (e.g., vegetarian, vegan, or low-salt diet) within 2 months prior to the start of screening.\n17. Specific lifestyle factors (e.g., night-shift work, extreme physical exertion) within 2 months prior to the start of screening.\n18. History of alcohol consumption exceeding 10 units per week (1 unit is equivalent to 500 mL of beer, 200 mL of wine, or 50 mL of spirits), or a medical history of alcoholism, drug addiction, or substance abuse.\n19. Smoking at the time of the screening visit.\n20. Piercing, tattoos, or permanent makeup performed within 1 month prior to screening or planned during the study.\n21. Mental, physical, or other reasons preventing the volunteer from adequately assessing their behavior and correctly following the Study Protocol requirements.\n22. Inability or unwillingness to comply with required contraceptive measures.\n23. Pregnancy (confirmed by a positive pregnancy test) or breastfeeding at the time of screening25.\n24. Participation in another clinical trial within 3 months prior to the start of screening.\n25. Other reasons that, in the investigator's opinion, preclude the volunteer's participation in this study.",{"count":659,"type":22},120,[316],"The primary objective of this study is to further define the mechanisms of action of Mexidol® (solution for intravenous and intramuscular injection, 50 mg\u002Fml) and Mexidol® FORTE 250 (film-coated tablets, 250 mg) in the hyperacute and acute periods of ischemic stroke, and to evaluate their impact on clinical and neuroimaging outcomes of the disease.",[26],[26,664,27,665,666,667,668,419,669,670,671,672],"Hyperacute Stroke","Cerebral Stroke","Acute Cerebrovascular Accident","ACVA","Acute cerebral failure","Neuroprotection","Mexidol","Ethylmethylhydroxypyridine Succinate","Antioxidants","2026-05-08",{"date":596,"type":43},{"date":676,"type":43},"2025-11-04",{"date":678,"type":22},"2027-04",{"name":680,"class":50},"Pharmasoft",9]